PremiumRatingsImmunovant’s Strategic Developments and Financial Strength Justify Buy Rating Immunovant, Inc. Reports Strategic Progress and Financial Results Immunovant reports Q4 EPS (64c), consensus (72c) PremiumThe FlyImmunovant downgraded to Neutral from Buy at UBS Immunovant’s Strategic Developments and Growth Potential Drive Buy Rating Immunovant’s Strategic Advancements and Targeted Approach Drive Buy Rating PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Buy Rating Affirmed for IMVT-1402: Promising Study Results and Strategic Focus in FcRn Space Immunovant price target raised to $61 from $58 at Stifel 
